Theolytics has dosed the first patient in a phase 1 clinical trial investigating intraperitoneal administration of THEO‑260 for women with platinum‑resistant ovarian cancer. T ...
Asgard Therapeutics will present new preclinical data on its lead asset AT‑108 in an oral presentation at the ASGCT Annual ...
AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...
The UK’s Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia (clesrovimab), ...
A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...
NICE recommends non‑hormonal therapy for moderate to severe vasomotor symptoms Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance ...
New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...
Herantis Pharma has dosed the first patients in the final cohort of its phase 1b clinical trial assessing HER-096, a disease-modifying treatment for Parkinson’s disease. The study aims to evaluate the ...
Study involves patients with advanced common cancers and solid tumours Study involves patients with advanced common cancers and solid tumours Exelixis has announced promising initial results from the ...
SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results